



**TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION  
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)**

Madrid, 18 June 2025

In compliance with the information duties provided for in article 227 of the Law 6/2023, of 17 March, on the Securities Markets and Investment Services, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, “**ROVI**” or the “**Company**”) hereby discloses to the Spanish National Securities Market Commission the following

**OTHER RELEVANT INFORMATION**

- I. The Ordinary General Shareholders’ Meeting held today, 18 June 2025, on first call, has approved all the proposed resolutions submitted by the Board of Directors to its approval and summarized as follows:
1. Approval of the individual financial statements of the Company and of the consolidated financial statements of the Company with its subsidiaries, as well as of the individual management report of the Company and the consolidated management report of the Company with its subsidiaries, all for the financial year ended 31 December 2024.
  2. Approval of the statement of non-financial information and sustainability information included in the consolidated management report of the Company with its subsidiaries for the year ended 31 December 2024.
  3. Approval of the proposal for the application of the individual profit for the year ended 31 December 2024, which includes the payment of a fixed dividend of 0.9351 euros gross per share entitled to receive it, which would imply the distribution of an amount approximately equivalent to 35% of the 2024 consolidated profit attributed to the parent company (*sociedad dominante*). The abovementioned amount will be paid on 16 July 2025.
  4. Approval of the management work and performance of the Board of Directors during the year ended 31 December 2024.
  5. Re-election of the following directors as members of the Board of Directors for the period specified by the Bylaws: Mr. Juan López-Belmonte Encina, Mr. Javier López-Belmonte Encina and Mr. Iván López-Belmonte Encina.
  6. Approval of the maximum annual remuneration of the members of the Board of Directors in their capacity as such for the 2025 financial year.
  7. Re-election of the auditors of the Company and its consolidated group for financial year 2025, KPMG Auditores, S.L.

8. Authorise the Board of Directors to proceed with the derivative acquisition of own shares by the Company and/or by its subsidiaries for the maximum period of five years.
9. Delegation to the Board of Directors of the power to increase the share capital under the terms and conditions of article 297.1b) of the Corporate Enterprises Act, for the maximum period of five years, with the attribution of the power to exclude the pre-emptive right up to the limit of 20% of the share capital, in accordance with the provisions of article 506 of the Corporate Enterprises Act.
10. Delegation to the Board of Directors of the power to issue bonds, debentures and other fixed-income securities, which may be exchanged and/or converted into the Company's shares, as well as warrants or other similar securities that may give the direct or indirect right to the subscription or acquisition of shares in the Company or other companies, whether or not in its Group, for a maximum period of 5 years and for a total amount of 500 million euros; and if necessary, the power to increase the share capital by the necessary amount with the attribution of the power to exclude pre-emptive rights up to the limit of 20% of the share capital, and authorisation that the Company may guarantee fixed-income issuance by subsidiaries.
11. Delegation of powers to formalise and register the resolutions adopted by the General Shareholders' Meeting and to carry out the mandatory filing of the financial statements.
12. Approval of the annual report on Directors' remuneration with an advisory vote.

The General Shareholders Meeting was also informed of the amendments to the Regulations of the Board of Directors of the Company resulting from certain amendments in relation to the functioning of the Audit Committee and the incorporation of certain improvements of a technical nature.

The text of the resolutions approved by the General Shareholders Meeting and the outcome of the voting will be published on the Company's website within the next five days.

- II. The Board of Directors of ROVI, at its meeting held today and following his re-election as director, has agreed to re-elect Mr. Juan López-Belmonte Encina as Chief Executive Officer (*Consejero Delegado*) of ROVI with all the powers of the Board of Directors that may be delegated by law or under the Bylaws, for the same term for which he has been re-elected as a member of the Company's Board of Directors.

Mr. Juan López-Belmonte Encina

Chairman of the Board of Directors and Chief Executive Officer (*Consejero Delegado*)  
Laboratorios Farmacéuticos ROVI, S.A.